Akari Therapeutics, Statistics
Total Valuation
AKTX has a market cap or net worth of $31.96 million. The enterprise value is $30.08 million.
Important Dates
The last earnings date was Wednesday, August 13, 2025, after market close.
Earnings Date | Aug 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
AKTX has 32.61 million shares outstanding. The number of shares has increased by 235.61% in one year.
Current Share Class | n/a |
Shares Outstanding | 32.61M |
Shares Change (YoY) | +235.61% |
Shares Change (QoQ) | +15.31% |
Owned by Insiders (%) | 80.31% |
Owned by Institutions (%) | 1.10% |
Float | 5.62M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.25 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19, with a Debt / Equity ratio of 0.03.
Current Ratio | 0.19 |
Quick Ratio | 0.16 |
Debt / Equity | 0.03 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -42.92 |
Financial Efficiency
Return on equity (ROE) is -112.02% and return on invested capital (ROIC) is -67.74%.
Return on Equity (ROE) | -112.02% |
Return on Assets (ROA) | -28.56% |
Return on Invested Capital (ROIC) | -67.74% |
Return on Capital Employed (ROCE) | -37.87% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.36M |
Employee Count | 9 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Dividends & Yields
AKTX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -235.61% |
Shareholder Yield | -235.61% |
Earnings Yield | -38.22% |
FCF Yield | -28.11% |
Analyst Forecast
The average price target for AKTX is $5.00, which is 410.20% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $5.00 |
Price Target Difference | 410.20% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on August 17, 2023. It was a reverse split with a ratio of 1:20.
Last Split Date | Aug 17, 2023 |
Split Type | Reverse |
Split Ratio | 1:20 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |